Proton Radiation—Yea or Nay?
Controversy over the value of proton beam radiation continues to harass clinicians as the therapy emerges to be extremely useful in some, but not all, cancers. Additionally, payers sometimes refuse to cover treatment costs due to lack of evidence of efficacy.
Marketplaces Will Have 25% More Insurers in 2015
The health insurance Marketplace will have 77 new insurers offering coverage in 2015, according to a report released by HHS. Overall, there will be a net 25% increase in the number of insurers that consumers will be able to choose from.
HHS Announces $99 Million in Grants to Improve Mental Health Services for Youth
HHS Secretary Sylvia M. Burwell announced $99 million to train new mental health providers, help teachers and others recognize mental health issues in youth and connect them to help, and increase access to mental health services for young people.
NIH Seeks Gender Equality in Research Studies
The National Institutes of Health announced disbursement of more than $10 million in research funding to researchers studying various healthcare issues. The objective of this additional funding is to avoid gender bias and seek equal representation of female subjects.
Number of Medicare Part D Drug Plans Down in 2015
Driven by a consolidation of offerings, the number of Part D prescription drug plans will decrease by 14% in 2015. While monthly premiums will decrease overall by 2%, there will be large premium variations.
Majority of Industry Stakeholders See No Value in Unique Health Plan Identifiers
Only a small proportion of industry stakeholders find any value in using the unique Health Plan Identifier within transactions, according to survey results from WEDI.
Updated International Consensus Guidelines for Advanced Breast Cancer Published
The guidelines have been published in 2 journals: Breast and Annals of Oncology.
Folowing AACR, ASCO Supports FDA's Guidance for LDTs
The ASCO statement corroborates the need for regulation of laboratory-developed tests, which are increasingly being used to guide personalized treatment in oncology as well as other therapeutic areas.
Dr Fridsma Leaves ONC to Be President and CEO of AMIA
Doug Fridsma, MD, PhD, FACP, FACMI, is leaving his position as the chief science officer for the Office of the National Coordinator for Health Information Technology to become the president and CEO of the American Medical Informatics Association.
Amgen's Blinatumomab Get's Breakthrough Status for ALL
The drug is the first in it's class — an antibody designed to engage 2 different targets simultaneously.
New Graphene Biosensor to Detect Cancer Biomarkers
The biosensor, which can detect the oxidative stress marker 8-hydroxydeoxyguanosine, is 5-times more sensitive than the ELISA test that is commonly used to identify biomarkers.
Introducing: American Association for Physician Leadership
In response to the growing recognition that physician leadership is essential to the successful transformation of healthcare, the American College of Physician Executives is becoming the American Association for Physician Leadership.
Lower Insurance Rates Saved Consumers $1 Billion in 2013
In 2013, lower health insurance rates saved consumers a total of $1 billion. States that enhanced their rate review programs will receive $25 million in rate review grant awards.
Small-Group Insurance Premium Variations Likely to Continue in the Near-Term
Since 2000, small-group health insurance premiums averaged annual increases of 5.5% nationally; however, double-digit increases were not uncommon, according to a report from the Urban Institute.
Microbubbles: New Carrier for Chemotherapy Delivery
The study, conducted in pancreatic cancer patients in Norway, was presented at the annual meeting of the International Contrast Ultrasound Society in Chicago.
Consumers Find ACA Insurance Plans Affordable
Although a majority of adults with health insurance purchased through the Affordable Care Act’s marketplace said they find it easy to afford the care they need, the number of people still enrolled has dipped to 7.3 million, according to recent numbers.
Gilead's Zydelig Receives EU Nod for CLL and FL
The approval in CLL is supported primarily by data from a randomized, placebo-controlled phase 3 trial in combination with rituximab in 220 patients with relapsed CLL who were not able to tolerate standard chemotherapy. The approval in FL, is supported by data from a single-arm phase 2 study (Study 101-09) of Zydelig monotherapy in 125 iNHL patients refractory to rituximab and alkylating-agent-containing chemotherapy.
GAO Report: Needs to Address Security Weaknesses
After examining the security and privacy of the website and its supporting systems at CMS, the Government Accountability Office published a report with 6 security management and 22 technical security recommendations.
In The Literature: Ramucirumab Improves OS in Advanced Gastric Cancer Patients
The study, published in Lancet Oncology, found that ramucirumab significantly improved survival by over 2 months.
Health IT Interoperability Roadmap in the Works
As part of National Health IT Week, the Office of the National Coordinator for Health IT, outlined its 10-year vision to achieve interoperability for health IT.
In The Literature: SNP Analysis Identifies New Prostate Cancer Susceptibility Loci
The study, published this week in Nature Genetics, is the product of an international collaboration that has identified 23 new loci that could lead to an increased risk of developing prostate cancer.
UK's NICE Wins Drug Price War With GSK
Although approved last September in the European Union, the National Institute for Health and Care Excellence had refused to cover the drug at the company-dictated price, which resulted in patients paying out-of-pocket.
Novo's Long-Acting Insulin, Tresiba, Safe and Effective
Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.
13% of Hospital Costs Motivated by Malpractice Fear
In a study of 3 hospitals in Massachusetts, more than a quarter of patient orders were considered partially defensive medicine, but they only accounted for 13% of costs.
Study Questions Screening Policy on Mammographically-Dense Breasts in Women
The study, published in the Journal of Clinical Oncology, wants a policy revamp on screening guidelines for the women who fall in this category.